Comprehensive Biomarker Testing
in Non-Small Cell Lung Cancer
Getting the right tests can help find your cancer’s weakness.
If you or someone you love has been diagnosed with non-small cell lung cancer (NSCLC), you’ve likely heard the phrase ‘biomarker testing’ and the need to wait for results. This wait can feel unbearable, but the science is clear: knowing what is driving your specific cancer before you start treatment can change everything about the care you receive.
This program will explain why comprehensive biomarker testing is the foundation of the right treatment plan.
Program Topics:
- What biomarker testing is and why it’s not inherited genetic testing.
- Why waiting for test results leads to better outcomes.
- Tissue vs. liquid biopsy: when and why both are needed.
- Common NSCLC biomarkers (EGFR, ALK, KRAS, ROS1, MET, PD-L1) and their treatment meaning.
- How targeted therapy, immunotherapy, and chemotherapy differ, and when to use each.
- What cancer progression means and why retesting is essential.
- How to advocate for yourself and be an active partner in your care.
Program Panel
Visit Our Partners
EGFR Resisters is a grassroots patient-driven community, dedicated exclusively to changing EGFR positive lung cancer into a manageable chronic disease. Their community of survivors and caregivers share knowledge and connect with others who are experiencing similar journeys. Find your community.
Program Sponsors
Thank you to our sponsors for their support of our independent patient education program. The Patient Story retains full editorial control over all content.
